VolitionRx (VNRX) Q2 2026 Earnings Call: Costs Fall as Nu.Q Pipeline Advances
Source Tradingkey
Key Takeaways
- VolitionRx Limited (NYSE American: VNRX) reported Q2 2026 revenue of approximately $0.4 million, broadly unchanged from Q2 2025. First-half revenue rose 112% year over year to $1.4 million.
- Q2 operating expenses fell 32% to $4.6 million from $6.7 million, reflecting the company’s cost-reduction program and a 27% year-over-year reduction in headcount.
- Net loss increased to $7.3 million from $6.3 million, primarily due to approximately $3 million of noncash accounting charges related to the Lind convertible notes.
- The Nu.Q NETs finger-prick lateral flow prototype showed approximately 90% correlation with the CE Mark automated assay in samples from critically ill patients with confirmed sepsis.
- Management is targeting a Nu.Q Lung Cancer reimbursement submission in France during Q3 2026, while emphasizing that reimbursement approval remains uncertain.
- Publication of the Nu.Q Vet feline cancer study is expected to trigger a $5 million contractual milestone payment. The prototype detected 86% of feline lymphomas at 97% specificity.
Key Financial Data
| Metric | Q2 2026 | Q2 2025 | Change / Commentary |
|---|---|---|---|
| Revenue | Approx. $0.4 million | Approx. $0.4 million | Broadly flat; higher Nu.Q Vet revenue was offset by lower Nu.Q Discover services revenue |
| First-half revenue | $1.4 million | — | Up 112% year over year |
| Operating expenses | $4.6 million | $6.7 million | Down 32% year over year |
| Operating loss | — | — | Down 34% year over year |
| Net loss | $7.3 million | $6.3 million | Increase mainly reflected approximately $3 million of noncash Lind note charges |
| Operating cash used | $5.2 million | $6.3 million | Lower year over year as cost savings began to take effect |
| Cash and cash equivalents | $2.8 million | $1.1 million at Dec. 31, 2025 | Q2 financing included $1.2 million from the ATM facility and $4.1 million from a public offering |
Disclaimer: For information purposes only. Past performance is not indicative of future results.
Recommended Articles
Gold Price Analysis Today: Gold Drops 1.32% Despite Lower Fed Rate-Hike Bets, Can $4,313 Support Hold?
Gold fell 1.32% on August 13 after rising to $4,449.73, then reversing lower and closing near $4,349.918 below the $4,356.46 support. Softer US inflation data reduced Fed rate hike expectations, but selling pressure still dominated the session. Will $4,313 support hold?
Gold fell 1.32% on August 13 after rising to $4,449.73, then reversing lower and closing near $4,349.918 below the $4,356.46 support. Softer US inflation data reduced Fed rate hike expectations, but selling pressure still dominated the session. Will $4,313 support hold?
Gold holds above $4,350 following weak US jobs data. As inflation reports approach and UBS eyes $5,000, can XAUUSD break resistance at $4,435 to rally toward $4,500?
Intel Corporation (NASDAQ: INTC) sits at $140.05, holding firm on the ascending trendline within the 2H timeframe. The RSI indicator is currently reading 55.21, positioning it as neutral-
On July 1, NVIDIA (NASDAQ: NVDA) sits at $198.34, failing to break above the former support level that is now serving as resistance between $198 and $205 on the 2H chart's downward blue c
Meta’s plan to sell surplus computing power hit chip stocks hard on Wall Street. Meta’s own shares climbed nearly 9% on the news.The announcement flipped years of assumed AI compute scarcity into a su
